

In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 7-9 without prejudice to their presentation in another application, and amend claims 1, 23, 29, and 31, as follows.

1. (currently amended) A vaccine composition comprising isolated inverted microsomes from an animal cell, or membrane fragments thereof, in association with a heterologous an externally disposed peptide antigen and a protein of the Major Histocompatibility Complex (MHC), wherein said peptide antigen and said protein of the MHC are externally disposed.
2. (original) A composition as claimed in claim 1, in which the microsome is from the endoplasmic reticulum of the cell.
3. (previously presented) A composition as claimed in claim 1, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.
4. (previously presented) A composition as claimed in claim 1, in which the composition additionally comprises one or more co-stimulatory molecules.
5. (previously presented) A composition as claimed in claim 4, in which the co-stimulatory molecules are selected from B7 and IL-2.
6. (previously presented) A composition as claimed in claim 1, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan origin.
- 7-10. (canceled).

11. (withdrawn) A method of treatment or prophylaxis of a subject suffering from a disease or condition, comprising administering to the subject a vaccine as claimed in claim 1 to treat said disease or condition.
12. (canceled).
13. (withdrawn) A method as claimed in claim 11, in which the disease is an infection caused by a virus, bacterium, yeast, fungus or protozoan.
14. (withdrawn) A method as claimed in claim 11, in which the disease is cancer.
15. (withdrawn) A method as claimed in claim 14, in which the cancer is melanoma, lung adenocarcinoma, colon cancer, breast cancer, or leukemia.
16. (withdrawn) A method as claimed in claim 11 in which the disease is an autoimmune condition.
17. (withdrawn) A use method as claimed in claim 16, in which the autoimmune condition is Multiple Sclerosis, Rheumatoid arthritis or Systemic Lupus Eryhamatosus.
18. (withdrawn) A process for the preparation of a vaccine composition as claimed in claim 1 comprising incubating a population of microsomes and an antigen in the presence of a nucleoside triphosphate, followed by processing to prepare inverted microsomes and formulating the resulting preparation in an physiological diluent and optionally an adjuvant.
19. (withdrawn) A process as claimed in claim 18, in which the microsome is from the endoplasmic reticulum of the cell.

20. (withdrawn) A process as claimed in claim 18, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.
21. (withdrawn) A process as claimed in claim 18, in which the protein of the MHC is from an autologous source with respect to the cell from which the microsomes are obtained.
22. (withdrawn) A process as claimed in claim 18, in which the composition additionally comprises one or more co-stimulatory molecules.
23. (withdrawn-currently amended) A process as claimed in claim 22, in which the co-stimulatory molecules are selected from B7 and IL-2.
24. (withdrawn) A process as claimed in claim 18, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan antigen.
25. (withdrawn) A process as claimed in claim 18, in which the antigen is an auto-antigen.
26. (withdrawn) A process as claimed in claim 18, in which the antigen is of neoplastic cell or cell of a cancer tumour, or a normal self-protein.
27. (withdrawn) A process as claimed in claim 26, in which the neoplastic cell or cancer cell tumour is from a melanoma, lung adenocarcinoma, colon cancer, breast cancer or leukemia cell.
28. (previously presented) A kit of parts comprising a composition as claimed in claim 1 and one or more cytokines and/or adjuvants in sealed containers.
29. (currently amended) A kit of parts as claimed in claim 28, in which the cytokine is IL-2 or IFN γ .

30. (previously presented) A kit of parts comprising a composition as claimed in claim 1 and one or more cytokines and/or adjuvants for separate, subsequent or simultaneous administration to a subject.

31. (currently amended) A kit of parts as claimed in claim 30, in which the cytokine is IL-2 or IFN γ .